iifl-logo

Dr Reddys Laboratories Ltd Cash Flow Statement

1,321.7
(-0.08%)
Sep 19, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Dr Reddys Labs FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

2,223.8

3,056.2

2,775.8

696.99

Depreciation

-814.3

-835

-789.2

-774.1

Tax paid

-600.6

-869.8

161.9

-130.1

Working capital

1,395.8

1,078.3

508.8

-170.1

Other operating items

Operating

2,204.7

2,429.7

2,657.3

-377.3

Capital expenditure

1,004.1

2,129.1

992.29

548.2

Free cash flow

3,208.8

4,558.8

3,649.6

170.9

Equity raised

33,530.3

29,823

23,896

23,007.52

Investing

287.5

-836.3

1,849

534.6

Financing

3,419.9

2,632.8

4,045.7

4,944

Dividends paid

0

0

0

331.82

Net in cash

40,446.5

36,178.3

33,440.3

28,988.84

Dr Reddys Labs : related Articles

US FDA Issues Form 483 With Five Observations at Dr Reddy’s Biologics Facility

The inspection, conducted between September 4 and September 12, 2025, was a pre-approval review.

15 Sep 2025|11:10 AM
Read More
Top Stocks for Today - 15th September 2025

Here are some of the stocks that may see significant price movement today: Apollo Hospitals, GMR Airports, RailTel Corporation, etc.

15 Sep 2025|07:44 AM
Read More
Dr Reddy’s Infuses ₹565 Cr into Russian Arm

The capital was infused via cash and will be used to support DRL Russia’s working capital requirements.

28 Jul 2025|12:22 PM
Read More
Dr Reddy’s Laboratories inks pact with Alvotech; stock gains ~3%

As per the terms agreement, Alvotech and Dr Reddy’s will jointly develop and manufacture the biosimilar candidate and share costs and responsibilities.

5 Jun 2025|11:00 AM
Read More
Dr. Reddy’s Receives Two USFDA Observations for New York API Manufacturing Plant

Issuance of a Form 483 occurs when an investigator(s) has observed any conditions that in their judgment may constitute violations of the FD&C Act and related Acts.

18 May 2025|07:17 PM
Read More
Dr Reddy’s Q4 Profit Jumps 22% to ₹1,594 Crore

The board has recommended a final dividend of ₹8 per equity share for FY 2024–25

12 May 2025|01:00 PM
Read More
Top Stocks for Today - 12th May 2025

Here are some of the stocks that may see significant price movement today: Adani Power, Dr Reddy's, and Bank of India, etc.

12 May 2025|09:32 AM
Read More
Dr. Reddy’s Laboratories Sells 14 ANDAs to Senores Pharma

Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.

5 Mar 2025|11:05 AM
Read More
Top Stocks for - 27th February 2025

Here are some of the stocks that may see significant price movement today: KPI Green, Tata Power, UltraTech Cement, etc.

26 Feb 2025|09:22 PM
Read More
Dr Reddy’s Hyderabad API Unit Gets USFDA VAI Classification

Dr Reddy's Laboratories third quarter net profit rose 2.5% year-on-year (YoY) to ₹1,413.3 crore. 

25 Feb 2025|08:42 PM
Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.